Precision Neuroscience
From Wikipedia, the free encyclopedia
 | |
| Company type | Private |
|---|---|
| Industry | Technology |
| Founded | 2021 |
| Founder | Benjamin Rapoport, Michael Mager, Demetrios Papageorgiou, Mark Hettick |
| Headquarters | New York City |
Key people | Michael Mager (CEO),[1] Benjamin Rapoport and Craig Mermel |
| Website | precisionneuro.io |
Precision Neuroscience is an American brain–computer interface (BCI) company based in New York City and with offices in Santa Clara, California and Addison, Texas.[2]
The company is building a minimally invasive brain–computer interface.[3] The interface includes a thin-film microelectrode array that conforms to the brain surface without penetrating the brain tissue. It collects hundreds of times higher resolution neural data than traditional cortical surface arrays. The procedure to implant the device does not require a craniotomy, and the implantation is designed to be reversible.[4] Precision Neuroscience aims to treat neurological conditions such as spinal cord injury, stroke, traumatic brain injury, and neurodegenerative conditions such as ALS.[1]
Precision Neuroscience was founded by Benjamin Rapoport, Michael Mager, Demetrios Papageorgiou, and Mark Hettick in 2021.[3] Rapoport is a neurosurgeon in the Mount Sinai Health System in New York City, where he specializes in minimally invasive surgery. Rapoport received a PhD in electrical engineering and computer science from the Massachusetts Institute of Technology and a medical degree from Harvard Medical School.[5] Rapoport was previously on the eight-member founding team at Elon Musk’s brain–computer interface company, Neuralink. Rapoport left Neuralink in 2018.[1]
Rapoport, along with Michael Mager, an investor, and a team of experts in areas such as neuroscience, microfabrication and software launched Precision Neuroscience in 2021.[1][6][4] Rapoport is the founding Chief Science Officer at Precision Neuroscience.[7] Mager is the founding Chief Executive Officer.[1]
In May 2021, Precision Neuroscience raised a $12 million Series A funding round led by Steadview Capital. In January 2023, the company raised a $41 million Series B funding round led by Forepont Capital Partners.[1] Other early investors in Precision Neuroscience included B Capital, Mubadala Capital, Draper Associates, Alumni Ventures, and re.Mind Capital.[4][8]
In June 2023, Precision Neuroscience completed its first-in-human clinical procedures, in collaboration with the Rockefeller Neuroscience Institute at West Virginia University, recording high-resolution neural activity from patients undergoing neurosurgery. In October 2023, Precision Neuroscience acquired a microelectromechanical systems MEMS manufacturing facility near Dallas, Texas, where the electrodes arrays are being manufactured.[7]
In May 2024, Precision Neuroscience and the Mount Sinai Health System announced a world record for the most electrodes simultaneously recording cortical activity from a human brain, deploying 4,096 electrodes across four Layer 7 arrays during a single procedure.[9]
In December 2024, Precision raised a $102 million Series C led by General Equity Holdings, with participation from B Capital, Duquesne Family Office, the investment firm of Stanley Druckenmiller, and Steadview Capital, at a post-money valuation of approximately $500 million.[10][11] As of January 2026, total funding stood at $180 million.[12]
In April 2025, the U.S. FDA granted 510(k) clearance for Precision’s Layer 7 Cortical Interface, authorizing commercial use for recording, monitoring, and stimulating on the brain’s surface for implantation durations of up to 30 days. Following FDA clearance, Precision Neuroscience began extended-duration implantation studies at six medical centers, allowing patients recovering from neurosurgery to use the device for up to 30 days in brain-computer interface tasks.[13]
In November 2025, Precision received an investment from SCI Ventures, a venture fund focused on spinal cord injury and paralysis, backed by the Christopher & Dana Reeve Foundation, Wings for Life, and Spinal Research.[14]
In January 2026, Precision Neuroscience and Medtronic formed a strategic partnership to co-develop an integrated system combining the Layer 7 cortical interface with Medtronic’s StealthStation surgical navigation platform.[12]
Technology
Precision Neuroscience is building a minimally invasive brain–computer interface.[3] Its system, called the Layer 7 Cortical Interface, makes contact with the brain surface using a thin-film microelectrode array that conforms to the surface of the brain without damaging brain tissue.[7] The array is one-fifth the thickness of a human hair and contains 1,024 microelectrodes,[15] yielding a spatial resolution hundreds of times higher than traditional electrode arrays. Together with customized supporting electronics and software, the device provides a high-resolution view of cortical activity in real-time. The array is modular, and multiple arrays can be linked to cover multiple cortical regions simultaneously.[4]
Precision Neuroscience developed a novel minimally invasive surgical procedure to implant the electrode arrays.[16] To implant the device, a surgeon makes a thin slit in the skull, less than a millimeter in width.[7] The system captures approximately one to two billion data points per patient per minute and uses AI algorithms to translate neural signals into computer commands in real time.[17]The company is developing a fully implantable, wireless version of the system intended for long-term use in patients with paralysis.[18]